- Sweden
- /
- Life Sciences
- /
- OM:AROC
AroCell Third Quarter 2024 Earnings: kr0.04 loss per share (vs kr0.056 loss in 3Q 2023)
AroCell (STO:AROC) Third Quarter 2024 Results
Key Financial Results
- Revenue: kr14.0m (up 31% from 3Q 2023).
- Net loss: kr9.84m (loss narrowed by 24% from 3Q 2023).
- kr0.04 loss per share (improved from kr0.056 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
AroCell Earnings Insights
Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Life Sciences industry in Sweden.
Performance of the Swedish Life Sciences industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with AroCell.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:AROC
AroCell
A vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers.
Excellent balance sheet and good value.